KR101061017B1 - 암세포의 성장 및/또는 전이 억제용 약학 조성물 - Google Patents

암세포의 성장 및/또는 전이 억제용 약학 조성물 Download PDF

Info

Publication number
KR101061017B1
KR101061017B1 KR1020090101003A KR20090101003A KR101061017B1 KR 101061017 B1 KR101061017 B1 KR 101061017B1 KR 1020090101003 A KR1020090101003 A KR 1020090101003A KR 20090101003 A KR20090101003 A KR 20090101003A KR 101061017 B1 KR101061017 B1 KR 101061017B1
Authority
KR
South Korea
Prior art keywords
seq
polypeptide
pro
asp
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020090101003A
Other languages
English (en)
Korean (ko)
Other versions
KR20110044374A (ko
Inventor
한장희
이선희
Original Assignee
(주) 수파드엘릭사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020090101003A priority Critical patent/KR101061017B1/ko
Application filed by (주) 수파드엘릭사 filed Critical (주) 수파드엘릭사
Priority to EP13191090.3A priority patent/EP2692353A3/en
Priority to US13/503,262 priority patent/US8530421B2/en
Priority to JP2012535105A priority patent/JP5751519B2/ja
Priority to CN2010800477400A priority patent/CN102711792A/zh
Priority to PCT/KR2010/005619 priority patent/WO2011049289A2/ko
Priority to EP10825114.1A priority patent/EP2491944A4/en
Publication of KR20110044374A publication Critical patent/KR20110044374A/ko
Application granted granted Critical
Publication of KR101061017B1 publication Critical patent/KR101061017B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020090101003A 2009-10-23 2009-10-23 암세포의 성장 및/또는 전이 억제용 약학 조성물 Active KR101061017B1 (ko)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1020090101003A KR101061017B1 (ko) 2009-10-23 2009-10-23 암세포의 성장 및/또는 전이 억제용 약학 조성물
US13/503,262 US8530421B2 (en) 2009-10-23 2010-08-24 Isolated polypeptides used for treatment of inflammatory diseases and inhibiting cancer metastasis
JP2012535105A JP5751519B2 (ja) 2009-10-23 2010-08-24 白血球の血管外遊出またはガン細胞の成長及び／もしくは転移を抑制するポリペプチドまたはその融合蛋白質
CN2010800477400A CN102711792A (zh) 2009-10-23 2010-08-24 抑制白细胞渗出或者癌细胞生长和/或转移的多肽或其融合蛋白
EP13191090.3A EP2692353A3 (en) 2009-10-23 2010-08-24 Peptide LGD or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis
PCT/KR2010/005619 WO2011049289A2 (ko) 2009-10-23 2010-08-24 백혈구의 혈관외유출 또는 암세포의 성장 및/또는 전이를 억제하는 폴리펩타이드 또는 그의 융합 단백질
EP10825114.1A EP2491944A4 (en) 2009-10-23 2010-08-24 POLYPEPTIDE OR FUSIONED PROTEIN THEREFORE FOR INHIBITING THE EXTRACATION OF LEUKOCYTES OR THE GROWTH AND / OR THE METASTASE OF CANCER CELLS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020090101003A KR101061017B1 (ko) 2009-10-23 2009-10-23 암세포의 성장 및/또는 전이 억제용 약학 조성물

Publications (2)

Publication Number Publication Date
KR20110044374A KR20110044374A (ko) 2011-04-29
KR101061017B1 true KR101061017B1 (ko) 2011-08-31

Family

ID=43900764

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020090101003A Active KR101061017B1 (ko) 2009-10-23 2009-10-23 암세포의 성장 및/또는 전이 억제용 약학 조성물

Country Status (6)

Country Link
US (1) US8530421B2 (https=)
EP (2) EP2491944A4 (https=)
JP (1) JP5751519B2 (https=)
KR (1) KR101061017B1 (https=)
CN (1) CN102711792A (https=)
WO (1) WO2011049289A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0689637B2 (ja) 1990-08-28 1994-11-09 株式会社荏原製作所 トンネル微気圧波低減装置
KR101644982B1 (ko) * 2015-07-23 2016-08-02 주식회사 엔솔바이오사이언스 신규 펩타이드 및 그 용도
ES2965061T3 (es) * 2016-03-02 2024-04-10 Univ Pittsburgh Commonwealth Sys Higher Education Nanovesículas unidas a matriz y su uso
US20200095296A1 (en) * 2017-06-05 2020-03-26 The Trustees Of Columbia University In The City Of New York Use of peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder and tcr and/or hla immunoprofiling in neurodegenerative disease
KR102268921B1 (ko) * 2019-12-10 2021-06-23 강원대학교산학협력단 p53을 활성화하는 펩타이드를 포함하는 조성물
EP4046647A4 (en) * 2019-12-11 2023-08-30 Supadelixir Inc. PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE WHICH INHIBITS THE INTERACTION OF P53 AND FOXO4
KR20230033097A (ko) * 2021-08-27 2023-03-08 (주)티카로스 기능이 강화된 신규 키메라 항원 수용체(car)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213279A1 (en) 2005-07-05 2008-09-04 Cornell Research Foundation, Inc. Blocking Leukocyte Emigration and Inflammation By Interfering With Cd99l2

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
EP1019438B1 (en) * 1997-09-30 2009-01-21 Peviva AB Apoptosis-related compounds and their use
EP1133317A1 (de) * 1998-11-26 2001-09-19 Pentapharm AG Transportsystemkonjugate
US6451969B1 (en) * 1999-01-15 2002-09-17 The Burnham Institute Methods for inhibiting tumor metastasis, and peptides useful therfor
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
ATE511856T1 (de) * 2000-03-13 2011-06-15 Cornell Res Foundation Inc Blockieren der leukozytenemigration und entzündung durch störung mit cd99/hec2
CH694935A5 (de) * 2000-07-26 2005-09-30 Straumann Holding Ag Oberflaechenmodifizierte Implantate.
US7460960B2 (en) * 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
US20050240009A1 (en) * 2002-08-21 2005-10-27 Carr Francis J T-cell epitopes in staphylococcal enterotoxin b
US7385027B2 (en) * 2003-01-07 2008-06-10 University Of Kentucky Research Foundation Membrane-permeable peptide capable of calpain inhibition
WO2005074986A2 (en) * 2004-02-10 2005-08-18 Genobiotix Aps Bioactive species capable of interfering with a microbial toxin-antitoxin complex and methods for evaluation and use of said bioactive species
KR100793949B1 (ko) * 2006-07-19 2008-01-16 강원대학교산학협력단 염증 질환의 예방 또는 치료 활성을 갖는 폴리펩타이드또는 그의 융합 단백질
KR100793947B1 (ko) * 2006-06-30 2008-01-16 강원대학교산학협력단 암세포의 성장 및 전이 억제 활성을 갖는 폴리펩타이드또는 그의 융합 단백질
WO2007037601A1 (en) 2005-09-28 2007-04-05 Knu-Industry Cooperation Foundation Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof
KR100941678B1 (ko) * 2007-12-17 2010-02-12 강원대학교산학협력단 암세포의 전이 억제 활성을 갖는 폴리펩타이드 또는 그의융합 단백질
KR101074005B1 (ko) * 2009-02-26 2011-10-17 재단법인춘천바이오산업진흥원 백혈구의 혈관외유출 억제 활성을 갖는 폴리펩타이드 또는 그의 융합 단백질

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213279A1 (en) 2005-07-05 2008-09-04 Cornell Research Foundation, Inc. Blocking Leukocyte Emigration and Inflammation By Interfering With Cd99l2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Research Vol.60(18):5134-5142 (2000. 9. 15.)

Also Published As

Publication number Publication date
EP2491944A2 (en) 2012-08-29
EP2692353A2 (en) 2014-02-05
WO2011049289A3 (ko) 2011-07-14
WO2011049289A2 (ko) 2011-04-28
CN102711792A (zh) 2012-10-03
JP5751519B2 (ja) 2015-07-22
JP2013507954A (ja) 2013-03-07
EP2692353A3 (en) 2014-03-26
US8530421B2 (en) 2013-09-10
EP2491944A4 (en) 2013-09-11
US20120245091A1 (en) 2012-09-27
KR20110044374A (ko) 2011-04-29

Similar Documents

Publication Publication Date Title
KR101061017B1 (ko) 암세포의 성장 및/또는 전이 억제용 약학 조성물
KR101463098B1 (ko) ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
CA2592292A1 (en) Sustained delivery of pdgf using self-assembling peptide nanofibers
CN102470156A (zh) 选择性作用于αvβ3整合素并缀合人血清白蛋白(HSA)变体的多肽及其药学用途
CN111808183B (zh) 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白
Lappi et al. The basic fibroblast growth factor‐saporin mitotoxin acts through the basic fibroblast growth factor receptor
CN109836501A (zh) 一种靶向her2的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
KR20090067214A (ko) 순차적 병용 요법
KR102934264B1 (ko) Sfrp2 길항제를 포함하는 조성물 및 방법
CN102030827B (zh) 一种高亲和力的抗her2单克隆抗体
TW201609793A (zh) 去整合蛋白變異體及其醫藥用途
CN110522909B (zh) 一种协同增强抗her2阳性肿瘤效果的药物组合
WO2010033249A2 (en) Compositions of and methods using ligand dimers
KR101074005B1 (ko) 백혈구의 혈관외유출 억제 활성을 갖는 폴리펩타이드 또는 그의 융합 단백질
KR101061016B1 (ko) 암세포의 성장 억제 및 염증 질환의 예방 또는 치료활성을 갖는 폴리펩타이드 또는 그의 융합 단백질
CN101798351B (zh) 人TIM-1-Fc融合蛋白的重组表达
KR100941678B1 (ko) 암세포의 전이 억제 활성을 갖는 폴리펩타이드 또는 그의융합 단백질
CN110343174A (zh) 一种高亲和力的黄热病毒人源单克隆抗体及其应用
JP2006513982A (ja) アンギオテンシンｉｉタイプ１レセプターに対するモノクローナル抗体の治療的使用方法
CN112028971A (zh) 抗肿瘤细胞转移和血管生成的靶向拮抗肽及其应用
Zur et al. Preventing osteoporotic bone loss in mice by promoting balanced bone remodeling through M-CSFRGD, a dual antagonist to c-FMS and αvβ3 receptors
KR20230109853A (ko) 항-vegfr2(kdr) 개량 항체를 포함하는 융합단백질 및 이의 용도
KR20230109854A (ko) 항-vegfr2(kdr) 개량 항체를 포함하는 융합단백질 및 이의 용도
CN109837304A (zh) 一种敲除pd1的靶向her2的嵌合抗原受体t细胞及其制备方法和应用
CN110343173B (zh) 一种高功能活性的黄热病毒人源单克隆抗体及其应用

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20140821

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20150817

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20160620

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20180920

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20190822

Year of fee payment: 9

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 14

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 15

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 15